SCHEMBL1308286

SCHEMBL1308286

O=C(Nc1ccc(Br)cc1C(=O)O)c1ccc(F)cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.57
TP53 P04637 1/20 0.55
AKR1C2 P52895 3/20 0.55
AKR1C1 Q04828 3/20 0.55
GPR35 Q9HC97 1/20 0.55
AKR1C4 P17516 1/20 0.54
AKR1C3 P42330 1/20 0.54
KCNK2 O95069 2/20 0.52
KCNK10 P57789 1/20 0.52
MAPT P10636 4/20 0.51
RAB9A P51151 2/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HDAC1 Q13547 1/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309186 0.89 AKR1C2 (0.58) NPC1TP53AKR1C2AKR1C1AKR1C4
SCHEMBL3846749 0.87 NPC1 (0.59) NPC1TP53GPR35MAPTRAB9A
SCHEMBL1307929 0.84 NPC1 (0.58) NPC1KCNK2MAPTALDH1A1GAA
SCHEMBL1307972 0.84 TP53 (0.70) NPC1TP53AKR1C2AKR1C1GPR35
SCHEMBL1307435 0.84 KCNK2 (0.57) NPC1TP53AKR1C2AKR1C1AKR1C4
SCHEMBL6352306 0.84 AVPR2 (0.56) NPC1TP53AKR1C2AKR1C1AKR1C4
SCHEMBL1308248 0.83 TAS1R3 (0.65) NPC1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL6360570 0.83 KCNK2 (0.68) AKR1C2AKR1C1GPR35AKR1C4AKR1C3
SCHEMBL23242595 0.82 NPC1 (0.55) NPC1TP53GPR35MAPTRAB9A
SCHEMBL29800850 0.82 NPC1 (0.55) NPC1TP53GPR35MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US claimed
US-8053454-B2 Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2011-11-08 US disclosed
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US disclosed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 PIM1, PIM3, PIM2 NPC1 3431/4885TP53 42/4885AKR1C2 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.